Silence TherapeuticsSLN -3.87%45 Return-on-Tangible-Equity is -132.67% as of Mar. 2026. GuruFocus rates SLN with a GF Score™ of 45/100 and a GF Value™ of $0.25 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,200 Biotechnology companies, Silence Therapeutics ranks worse than 92.42% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Silence Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was $-59.83 Mil. Silence Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $45.10 Mil. Therefore, Silence Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -132.67%.
The historical rank and industry rank for Silence Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
SLN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -4292.9 Med: -100.41 Max: -3.73
Current: -329.91
During the past 13 years, Silence Therapeutics's highest Return-on-Tangible-Equity was -3.73%. The lowest was -4,292.90%. And the median was -100.41%.
SLN's Return-on-Tangible-Equity is ranked worse than 92.42% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs SLN: -329.91
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Silence Therapeutics Return-on-Tangible-Equity Related Terms
Silence Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Silence Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLN vs IMRX, VRXA, MGNX: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Silence Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silence Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Silence Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -132.67% mean?
Silence Therapeutics (SLN) has a Return-on-Tangible-Equity of -132.67% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Silence Therapeutics and its competitors. According to the industry distribution chart, Silence Therapeutics ranks #1109 out of 1200 companies in the Biotechnology industry, placing it in the top 92.4%.
Is Silence Therapeutics' Return-on-Tangible-Equity too high?
Silence Therapeutics' current Return-on-Tangible-Equity is -132.67%. Based on the distribution chart, Silence Therapeutics ranks #1109 out of 1200 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Silence Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Return-on-Tangible-Equity compare to IMRX and VRXA?
According to the Biotechnology industry distribution chart, Silence Therapeutics ranks #1109 out of 1200 companies for Return-on-Tangible-Equity. This places Silence Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Silence Therapeutics and its competitors. Silence Therapeutics's current Return-on-Tangible-Equity is -132.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.25, compared to a current price of $10.55 — trading 4118% above its estimated fair value. The current Return-on-Tangible-Equity is -132.67%. Silence Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current Return-on-Tangible-Equity is -132.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Silence Therapeutics (SLN) Overvalued in 2026?
Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued.
The current stock price of $10.55 is trading 4118% above its estimated GF Value™ of $0.25.
GuruFocus considers Silence Therapeutics to be Significantly Overvalued.
Key valuation signals for SLN:
Return-on-Tangible-Equity: -132.67%
GF Value™: $0.25 vs. price of $10.55 (4118% above fair value)
No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
45GF Score
Get the complete analysis for SLN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLN has been successfully added to your 
